KLRC1 and neoplasm: Notably, our findings also support the requirement of enhancing the generation of anti-tumor innate and adaptive immunity effectors using immunomodulatory drugs such as CBL0137 to increase the therapeutic efficacy of immune checkpoint-based immunotherapy, including anti-NKG2A antibodies.